...
首页> 外文期刊>BMC Musculoskeletal Disorders >A case of Schnitzler’s syndrome without monoclonal gammopathy successfully treated with canakinumab
【24h】

A case of Schnitzler’s syndrome without monoclonal gammopathy successfully treated with canakinumab

机译:用Canakinumab成功治疗了没有单克隆血管病的施尼茨勒综合征的情况

获取原文
           

摘要

Schnitzler’s syndrome (SchS) is a rare autoinflammatory syndrome with diagnostic challenge and be characterized by chronic urticaria, a monoclonal gammopath, periodic fever and bone pain. In addition to the monoclonal gammopathy, bone abnormalities are often found at the site of bone pain in patients with SchS. The remarkable efficacy of interleukin-1 (IL-1) inhibition was also demonstrated in this syndrome. We describe a case of refractory chronic urticaria presenting with clinical manifestations consistent with SchS without monoclonal gammopathy. A 43-year-old female patient suffering from recurring of urticaria with periodic fever as well as bone pain for the past 4?years. The patient had leukocytosis and elevated levels of C-reactive protein (CRP) and serum amyloid A (SAA). PET/CT (positron emission tomography/computed tomography) and MRI (magnetic resonance imaging) examination revealed hyper-metabolism areas in both femoral bone marrow. Although bone marrow histology revealed no abnormality, urticarial skin lesions shows neutrophilic infiltrations without evidence of vasculitis. We could not exclude the possibility of SchS. The patient had been treated with antihistamines, steroids, omarizumab, colchicine and cyclosporine A, no therapeutic effect was observed. She was started on canakinumab 150?mg subcutaneous injection with 4?weeks interval. Within 48?h after the first injection, the urticarial rash disappeared, and febrile attack and bone pain had not recurred. Elevated levels of serum CRP and SAA were normalized within a week after the first injection of canakinumab. The current case suggests an important role for IL-1 as a mediator in the pathophysiology of SchS-like refractory urticaria with bine pain. It had been presumed that monoclonal gammopathy may not always present in SchS. It is important to avoid delay in diagnosis and initiation of proper treatment in SchS or autoinflammatory conditions resembling SchS.
机译:斯科尼茨勒的综合征(SCHS)是一种罕见的自身炎症综合征,具有诊断挑战,其特征是慢性荨麻疹,单克隆γ,周期性发烧和骨疼痛。除了单克隆血管病,骨异常通常在SCHS患者的骨疼痛部位发现。在该综合征中还证明了白细胞介素-1(IL-1)抑制的显着效果。我们描述了一种难治性慢性荨麻疹的案例,呈现出与没有单克隆γ肠道的SCHs一致的临床表现。一名43岁的女性患者患有荨麻疹的重复,过去4年的骨痛以及骨痛。患者具有白细胞增多和升高的C反应蛋白(CRP)和血清淀粉样蛋白A(SAA)。 PET / CT(正电子排放断层扫描/计算断层扫描)和MRI(磁共振成像)检查显示股骨骨髓中的超代谢区域。虽然骨髓组织学没有显示出异常,但荨麻疹皮肤病变显示中性渗透性,没有血管炎的证据。我们无法排除SCHS的可能性。患者已被抗组胺药,类固醇,奥马米,血清序列和环孢菌素A治疗,未观察到治疗效果。她开始在Canakinumab 150?Mg皮下注射,4个?周间隔。在第一次注射后48℃内,荨麻疹皮疹消失,发热攻击和骨痛没有重新发生。在第一次注射加坎诺伊人后一周内升高的血清CRP和SAA水平。目前的案例表明IL-1作为具有沸点疼痛的SCHS样难治性荨麻疹病理生理学中的介质的重要作用。已经推测,单克隆血管病可能并不总是存在于SCHS中。重要的是要避免延迟诊断和在Schs或自身炎症条件下适当治疗的诊断和启动。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号